By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Ophthalmic glaucoma agents > Miostat > Miostat Prescribing Information
Ophthalmic glaucoma agents
https://themeditary.com/pro/miostat-prescribing-information-13825.html

Miostat Prescribing Information

Drug Detail:Miostat (Carbachol ophthalmic [ kar-ba-kall ])

Drug Class: Ophthalmic glaucoma agents

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Miostat Description

MIOSTAT™ (carbachol intraocular solution, USP) 0.01% is a sterile balanced salt solution of carbachol for intraocular injection. The active ingredient is represented by the chemical structure:


chemical

Established Name: Carbachol
Chemical Name: Ethanaminium, 2-[(aminocarbonyl)oxy]-N,N,Ntrimethyl-, chloride.
Molecular Formula: C6H15CIN2O2
Molecular Weight: 182.65

Each mL of MIOSTAT™ (carbachol intraocular solution, USP) 0.01%contains: Active: carbachol 0.01%.
Inactives: sodium chloride 0.64%, potassium chloride 0.075%, calcium chloride dehydrate 0.048%, magnesium chloride hexahydrate 0.03%, sodium acetate trihydrate 0.39%, sodium citrate dihydrate 0.17%, sodium hydroxide and/or hydrochloric acid (to adjust pH) and Water for Injection. pH range is 6.5-7.5.

Miostat - Clinical Pharmacology

Carbachol is a potent cholinergic (parasympathomimetic) agent which produces constriction of the iris and ciliary body resulting in reduction in intraocular pressure (IOP). The exact mechanism by which carbachol lowers IOP is not precisely known.

Related/similar drugs

latanoprost ophthalmic, acetazolamide, timolol ophthalmic, brimonidine ophthalmic, pilocarpine ophthalmic, Lumigan, Xalatan

Indications and Usage for Miostat

Intraocular use for obtaining miosis during surgery. In addition, MIOSTAT* (carbachol intraocular solution, USP) 0.01% reduces the intensity of IOP elevation in the first 24 hours after cataract surgery.

Contraindications

Should not be used in those persons showing hypersensitivity to any of the components of this preparation.

Warnings

For single-dose intraocular use only. Discard unused portion. Intraocular carbachol 0.01% should be used with caution in patients with acute cardiac failure, bronchial asthma, peptic ulcer, hyperthyroidism, G.I. spasm, urinary tract obstruction and Parkinson's disease. The vial stopper contains natural rubber (latex) which may cause severe allergic reactions.

Precautions

Use only if the container is undamaged.

Carcinogenesis:

Studies in animals to evaluate the carcinogenic potential have not been conducted.

Pregnancy:

There are no adequate and well-controlled studies in pregnant women. MIOSTAT* (carbachol intraocular solution, USP) 0.01% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers:

It is not known if this medication is excreted in breast milk. Exercise caution when administering to a nursing woman.

Pediatric Use:

Safety and efficacy in pediatric patients have not been established.

Geriatric Use:

No overall differences in safety or effectiveness have been observed between elderly and younger patients.

Adverse Reactions/Side Effects

Ocular: Corneal clouding, persistent bullous keratopathy, retinal detachment and postoperative iritis following cataract extraction have been reported.

Systemic: Side effects such as flushing, sweating, epigastric distress, abdominal cramps, tightness in urinary bladder, and headache have been reported with topical or systemic application of carbachol.

The following additional reactions have been identified during post-approval use of MIOSTAT (carbachol intraocular solution, USP) 0.01% in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to MIOSTAT, or a combination of these factors, include: corneal edema, drug effect prolonged (miosis), eye inflammation, eye pain, intraocular pressure increased, ocular hyperemia, vision blurred, visual impairment, and vomiting.

Miostat Dosage and Administration

Aseptically remove the sterile vial from the blister package by peeling the backing paper and dropping the vial onto a sterile tray. Withdraw the contents into a dry sterile syringe, and replace the needle with an atraumatic cannula prior to intraocular instillation. No more than one-half milliliter should be gently instilled into the anterior chamber for the production of satisfactory miosis. It may be instilled before or after securing sutures. Miosis is usually maximal within two to five minutes after application.

How is Miostat supplied

In a 2.0 mL glass vial with a 1.5 mL fill, grey butyl stopper and aluminum seal packaged twelve to a carton…………………………………………………………………………..NDC 0065-0023-15

STORAGE: Store at 15° - 30°C (59° - 86°F).

© 2021 Alcon Inc.

Distributed by:
Alcon Laboratories, Inc.
Fort Worth, Texas 76134

300048977-0621

PRINCIPAL DISPLAY PANEL

NDC 0065-0023-15

MIOSTAT™

(CARBACHOL INTRAOCULAR
SOLUTION, USP) 0.01%

TWELVE
1.5 mL Sterile Glass Vials
Alcon Laboratories, Inc., Fort Worth, Texas 76134 USA

Alcon

USUAL DOSAGE: 0.5 mL

STORAGE: Store at 15 - 30C (59 - 86F).

WARNING: For single-dose intraocular use only. Discard unused portion.

Rx Only

INGREDIENTS: A sterile balanced salt solution containing (per mL) Active:
carbachol 0.01%. Inactives: sodium chloride 0.64%, potassium chloride
0.075%, calcium chloride dihydrate 0.048%, magnesium chloride
hexahydrate 0.03%, sodium acetate trihydrate 0.39%, sodium citrate
dihydrate 0.17%, sodium hydroxide and/or hydrochloric acid (to adjust
pH) and water for injection.

GTIN: 10300650023150

S/N:

LOT:

EXP.:

300048975-0621

Carton Label

NDC 0065-0023-15

MIOSTAT
*
(CARBACHOL INTRAOCULAR SOLUTION, USP) 0.01%

TWELVE
1.5 mL Sterile Glass Vials
Alcon Laboratories, Inc., Fort Worth, Texas 76134 USA
* a trademark of Novartis
©2004, 2013, 2015 Novartis

Alcon®
a Novartis company
USUAL DOSAGE: 0.5 mL

STORAGE: Store at 15 - 30C (59 - 86F).

Rx Only

INGREDIENTS: A sterile balanced salt solution containing (per mL) Active: carbachol 0.01%. Inactives: sodium chloride 0.64%, potassium chloride 0.075%, calcium chloride dihydrate 0.048%, magnesium chloride hexahydrate 0.03%, sodium acetate trihydrate 0.39%, sodium citrate dihydrate 0.17%, sodium hydroxide and/or hydrochloric acid (to adjust pH) and water for injection.

GTIN: 10300650023150

S/N

LOT:

EXP.:

9011781-0415

Carton Label

MIOSTAT™
(carbachol intraocular solution, USP) 0.01%


Alcon

300056865

LOT: EXP.:

Bottle Label

MIOSTAT®
(carbachol intraocular solution, USP) 0.01%


Alcon®

© 2001, 2018 Alcon, Inc.

H15348-0718

LOT: EXP.:

label

LOT: EXP: 305190-1104

NDC 0065-0023-15

MIOSTAT®
(CARBACHOL INTRAOCULAR SOLUTION, USP) 0.01% 1.5mL

Rx Only. Sterile Unless Package Open or Damaged Read enclosed insert. INGREDIENTS: Active: carbachol 0.01%. Inactives: sodium chloride 0.64%, potassium chloride 0.075%, calcium chloride dihydrate 0.048%, magnesium chloride hexahydrate 0.03%, sodium acetate trihydrate 0.39%, sodium citrate dihydrate 0.17%, sodium hydroxide and/or hydrochloric acid (to adjust pH) and water for injection. USUAL DOSAGE: 0.5mL STORAGE: Store at 15° - 30°C (59° - 86°F).

©2004 Alcon, Inc. Alcon Labs., Inc. Fort Worth, TX. 76134

backing paper

MIOSTAT
carbachol solution
Product Information
Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:0065-0023
Route of AdministrationOPHTHALMIC
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
CARBACHOL (UNII: 8Y164V895Y) (Carbamoylcholine - UNII:54Z8M50D6Q) CARBACHOL0.1 mg in 1 mL
Inactive Ingredients
Ingredient NameStrength
SODIUM CHLORIDE (UNII: 451W47IQ8X)
POTASSIUM CHLORIDE (UNII: 660YQ98I10)
CALCIUM CHLORIDE (UNII: M4I0D6VV5M)
MAGNESIUM CHLORIDE (UNII: 02F3473H9O)
SODIUM ACETATE (UNII: 4550K0SC9B)
TRISODIUM CITRATE DIHYDRATE (UNII: B22547B95K)
SODIUM HYDROXIDE (UNII: 55X04QC32I)
HYDROCHLORIC ACID (UNII: QTT17582CB)
WATER (UNII: 059QF0KO0R)
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:0065-0023-1512 in 1 CARTON04/15/1974
11.5 mL in 1 VIAL, GLASS; Type 0: Not a Combination Product
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA01696804/15/1974
Labeler - Alcon Laboratories, Inc. (008018525)
Registrant - Alcon Laboratories, Inc. (008018525)
Establishment
NameAddressID/FEIBusiness Operations
Alcon Research LLC007672236manufacture(0065-0023)
Establishment
NameAddressID/FEIBusiness Operations
Siegfried AG482824026api manufacture(0065-0023)

Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by